
    
      This is a Phase 2a, single-center, randomized, placebo-controlled, double-blind study that
      includes 12 weeks of treatment with experimental drug anti-inflammatory agent or placebo TID
      administered orally.

      All subjects will be â‰¥18 years, have sinusitis with persistent symptoms despite standard of
      care treatment, and have failed a course of steroids in the past.
    
  